维尔达格利普汀
大疱性类天疱疮
糖尿病
医学
利格列汀
药品
皮肤病科
类天疱疮
2型糖尿病
药理学
内分泌学
免疫学
抗体
作者
Havva Özge Keseroğlu,Gamze Taş-Aygar,Müzeyyen Gönül,Özay Gököz,Sibel Ersoy‐Evans
标识
DOI:10.1080/15569527.2016.1211670
摘要
Bullous pemfigoid (BP), an autoimmune disorder, can also be induced by some medications. Vildagliptin is a new drug used to treat diabetes mellitus (DM). Recently, a few cases of vildagliptin-induced BP have been described in the literature. We report a patient with BP in which vildagliptin was thought to be as a possible causative agent. The awareness of BP development risk during gliptin therapy can prevent unnecessary usage of systemic drugs with serious side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI